Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-869 plus paclitaxel versus paclitaxel alone in first-line metastatic breast cancer
2007-005949-38Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing ABT-869 + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jun 2008; status: terminated.
02
Drugs
linifanibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-005949-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005949-38.